Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors

Biochemical and Biophysical Research Communications

Volumn 368, Issue 2, 2008, Pages 318-322

  Park, Jung Hyun ^a   Kim, Sung Hak ^a   Choi, Moon Chang ^a   Lee, Juhee ^a   Oh, Do Youn ^a,b   Im, Seock Ah ^a,b   Bang, Yung Jue ^a,b   Kim, Tae You ^a,b  

^a Cancer Research Center   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Heat shock protein; Histone deacetylase inhibitor; LAQ824; Proteasome; SAHA; Vascular endothelial growth factor receptor

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; PROTEASOME; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VORINOSTAT;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH;

CELL LINE, TUMOR; HISTONE DEACETYLASES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LUNG NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; STOMACH NEOPLASMS;

EID: 39549088498     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.01.056     Document Type: Article

References (26)

1. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
2. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9 (2006) 225-230 discussion 231
3. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18 (1997) 4-25
4. Karkkainen M.J., and Petrova T.V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19 (2000) 5598-5605
5. Cross M.J., Dixelius J., Matsumoto T., and Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem. Sci. 28 (2003) 488-494
6. Bicknell R., and Harris A.L. Novel angiogenic signaling pathways and vascular targets. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 219-238
7. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. Exs (2005) 209-231
8. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem. Soc. Trans. 31 (2003) 1171-1177
9. Brader S., and Eccles S.A. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 90 (2004) 2-8
10. Rakic J.M., Maillard C., Jost M., Bajou K., Masson V., Devy L., Lambert V., Foidart J.M., and Noel A. Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell. Mol. Life Sci. 60 (2003) 463-473
11. Rundhaug J.E. Matrix metalloproteinases and angiogenesis. J. Cell Mol. Med. 9 (2005) 267-285
12. Bingle L., Brown N.J., and Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196 (2002) 254-265
13. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1 (2002) 287-299
14. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1 (2001) 194-202
15. Byrd J.C., Marcucci G., Parthun M.R., Xiao J.J., Klisovic R.B., Moran M., Lin T.S., Liu S., Sklenar A.R., Davis M.E., Lucas D.M., Fischer B., Shank R., Tejaswi S.L., Binkley P., Wright J., Chan K.K., and Grever M.R. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105 (2005) 959-967
16. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., MacGregore-Cortelli B., Tong W., Secrist J.P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P.A., Scher H., and Richon V.M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23 (2005) 3923-3931
17. Warrener R., Beamish H., Burgess A., Waterhouse N.J., Giles N., Fairlie D., and Gabrielli B. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J. 17 (2003) 1550-1552
18. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., Rocha K., Kumaraswamy S., Boyapalle S., Atadja P., Seto E., and Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280 (2005) 26729-26734
19. Fiskus W., Ren Y., Mohapatra A., Bali P., Mandawat A., Rao R., Herger B., Yang Y., Atadja P., Wu J., and Bhalla K. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin. Cancer Res. 13 (2007) 4882-4890
20. Fuino L., Bali P., Wittmann S., Donapaty S., Guo F., Yamaguchi H., Wang H.G., Atadja P., and Bhalla K. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2 (2003) 971-984
21. Sanderson S., Valenti M., Gowan S., Patterson L., Ahmad Z., Workman P., and Eccles S.A. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol. Cancer Ther. 5 (2006) 522-532
22. Ku J.L., and Park J.G. Biology of SNU Cell Lines. Cancer Res. Treat. 37 (2005) 19
23. Park J.H., Jung Y., Kim T.Y., Kim S.G., Jong H.S., Lee J.W., Kim D.K., Lee J.S., Kim N.K., Kim T.Y., and Bang Y.J. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res. 10 (2004) 5271-5281
24. Yu X., Guo Z.S., Marcu M.G., Neckers L., Nguyen D.M., Chen G.A., and Schrump D.S. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 94 (2002) 504-513
25. Chen L., Meng S., Wang H., Bali P., Bai W., Li B., Atadja P., Bhalla K.N., and Wu J. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol. Cancer Ther. 4 (2005) 1311-1319
26. Di Gennaro E., Bruzzese F., Caraglia M., Abruzzese A., and Budillon A. Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids 26 (2004) 435-441